⌕
Nurix Therapeutics · NRIX · Nasdaq
Tenet 85 · Strong
Compare
$14.67−5.23%At closeTenet 85 · Strong
$14.67−0.81 (−5.23%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
$14.99+0.32 (+2.18%)
After hours: Nov 16, 2026, 4:14 PM ET

Nurix Therapeutics (NRIX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~29.6%/yr (FY21→FY25), net margin −314.9%. Worth your attention in FY25: Share count (+102.0%) and Capex step-up ($14.0M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲54.0%
84.0
FY21→FY25CAGR +29.6%/yr
Net income ($M)▼36.6%
−264.5
FY21→FY25CAGR —
Free cash flow ($M)▼44.9%
−263.5
capex stepped upCAGR —
Diluted EPS▼5.9%
−3.05
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+102.0%

42.9mn → 86.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$14.0M

▲51% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)84.0Revenue0.0COGS84.0Gross profit−316.9R&D−52.7SG&A−285.7Op income21.2Tax & other−264.5Net income

-315¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~4%FY21FY25

Over this window: gross 100.0% → 100.0%. Net margin -314.9% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7461, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
701,936.083,980.054,549.076,987.038,627.029,750.0▲54.0%+29.6%
Cost of revenue
—0.00.00.00.00.0——
Gross profit
701,936.083,980.054,549.076,987.038,627.029,750.0▲54.0%+29.6%
Research & development
334,074.0316,903.0221,632.0189,148.0184,497.0116,434.0▲43.0%+28.4%
Selling, general & admin
78,205.052,743.045,944.042,902.037,997.031,202.0▲14.8%+14.0%
Total operating expenses
412,279.0369,646.0267,576.0232,050.0222,494.0147,636.0▲38.1%+25.8%
Operating incomefeeds ROC rank
289,657.0−285,666.0−213,027.0−155,063.0−183,867.0−117,886.0▼34.1%—
Other income, net
18,555.021,969.019,728.011,115.03,507.0823.0——
Pretax income
308,212.0−263,697.0−193,299.0−143,948.0−180,360.0−117,063.0▼36.4%—
Income tax
—760.0270.00.00.0131.0▲181.5%+55.2%
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
294,877.0−264,457.0−193,569.0−143,948.0−180,360.0−117,194.0▼36.6%—
Per share
Diluted EPSbuyback-sensitive
2.30−3.05−2.88−2.65−3.71−2.73▼5.9%—
Diluted shares (mn)
116.1586.6767.1254.3448.6142.90▲29.1%+19.2%
Margins
Gross margin
100.0%100.0%100.0%100.0%100.0%100.0%▲0.0pp+0.0pp
Operating margin
41.3%−340.2%−390.5%−201.4%−476.0%−396.3%▲50.4pp+56.1pp
Net margin98th pct in Healthcare
42.0%−314.9%−354.9%−187.0%−466.9%−393.9%▲39.9pp+79.0pp
† TTM = trailing four quarters through 2026-08-31.
FY19 – FY20 · 2 more years
Unlock the full history →
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-01-28 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Nurix Therapeutics' revenue last fiscal year?

Nurix Therapeutics reported revenue of $84.0M in fiscal 2025, up 54.0% from fiscal 2024.

What was Nurix Therapeutics' net income?

Nurix Therapeutics reported net income of −$264.5M in fiscal 2025, a net margin of −314.9%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.